Research progress in minimal residual disease in locally advanced non-small cell lung cancer
10.3760/cma.j.cn113030-20220920-00315
- VernacularTitle:局部晚期非小细胞肺癌微小残留病灶的研究进展
- Author:
Wanting ZHANG
1
;
Xu YANG
;
Zhouguang HUI
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Keywords:
Carcinoma, non-small-cell lung;
Chemoradiotherapy;
Circulating tumor DNA;
Minimal residual disease;
Recurrence;
Consolidation therapy
- From:
Chinese Journal of Radiation Oncology
2023;32(10):939-944
- CountryChina
- Language:Chinese
-
Abstract:
For locally advanced unresectable non-small cell lung cancer (NSCLC), the standard regimen is concurrent chemoradiotherapy (CCRT) followed by consolidation immunotherapy. Nevertheless, the majority of patients will experience recurrence. Traditional imaging examination has its limitations of passively identifying recurrence, unable to forecast the risk in advance. Minimal residual disease (MRD) based on circulating tumor DNA (ctDNA) has become a novel tumor biomarker. Existing studies have demonstrated that the levels of ctDNA initially increase and then decrease during CCRT for NSCLC. Monitoring ctDNA-MRD can not only robustly predict recurrence, but also guide the consolidation immunotherapy, evaluate the efficacy and predict clinical prognosis. Furthermore, ctDNA-MRD can be a reliable biomarker to explore other effective treatments. However, few ctDNA-MRD clinical studies related to guiding consolidation therapy have been performed, with small sample size and low-level evidence. The value of ctDNA-MRD still needs to be confirmed by prospective randomized studies.
